テルイ ヤスヒト
TERUI Yasuhito
照井 康仁 所属 埼玉医科大学 医学部 血液内科 職種 教授 |
|
論文種別 | 学術雑誌(原著) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma |
掲載誌名 | 正式名:Int J Hematol ISSNコード:18653774 |
掲載区分 | 国外 |
巻・号・頁 | 113,370-380頁 |
著者・共著者 | Izutsu, K., Yamamoto, K., Kato, K., Ishikawa, T., Fukuhara, N., Terui, Y., Choi, I., Humphrey, K., Kim, S. Y., Okubo, S., Ogawa, N., Nishimura, Y., Salem, A. H., Maruyama, D. |
発行年月 | 2021 |
概要 | Venetoclax is a potent BCL-2 inhibitor that induces apoptosis in CLL cells. This open-label, phase 1/2 study evaluated the safety, pharmacokinetics, and efficacy of venetoclax in Japanese patients with R/R CLL/SLL. Patients enrolled in phase 1 received 400 mg/day venetoclax monotherapy. Patients enrolled in phase 2 received 400 mg/day venetoclax, plus rituximab. Venetoclax was administered with a weekly stepwise ramp-up in doses. In phase 2, efficacy was evaluated by objective response rate (ORR). Twelve patients were enrolled, six in each arm. The most common grade ≥ 3 adverse events were neutropenia (83%), lymphopenia (67%), leukopenia (33%), and thrombocytopenia (17%). Patients receiving venetoclax monotherapy achieved an ORR of 100%, including a complete remission (CR) rate of 17%. Patients receiving combination therapy had an ORR of 67% and a CR rate of 50%. |
DOI | 10.1007/s12185-020-03024-3 |
文献番号 | 33094474 |